Detalhe da pesquisa
1.
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Ann Oncol
; 34(2): 173-185, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414192
2.
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Ann Oncol
; 33(5): 466-487, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35176458
3.
The burden of COVID-19 infection in a rural Tamil Nadu community.
BMC Infect Dis
; 21(1): 1110, 2021 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711193
4.
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Ann Oncol
; 31(4): 507-516, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32139298
5.
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Ann Oncol
; 31(11): 1536-1544, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861806
6.
Molecular mechanisms in grass-Epichloë interactions: towards endophyte driven farming to improve plant fitness and immunity.
World J Microbiol Biotechnol
; 36(7): 92, 2020 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32562008
7.
Verifying measurements of residual calcium content in demineralised cortical bone.
Cell Tissue Bank
; 20(4): 527-534, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456097
8.
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
Ann Oncol
; 29(suppl_1): i20-i27, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29462255
9.
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Ann Oncol
; 29(8): 1701-1709, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29905778
10.
Quantifying the ultrastructure changes of air-dried and irradiated human amniotic membrane using atomic force microscopy: a preliminary study.
Cell Tissue Bank
; 19(4): 613-622, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30056604
11.
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
Ann Oncol
; 28(12): 3037-3043, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950351
12.
Fast and parallel determination of PCB 77 and PCB 180 in plasma using ultra performance liquid chromatography with diode array detection: A pharmacokinetic study in Swiss albino mouse.
Biomed Chromatogr
; 31(11)2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485018
13.
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ann Oncol
; 27(3): 423-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26768165
14.
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ann Oncol
; 26(8): 1741-8, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25997818
15.
Analysis of liver-directed therapies in U.S. cancer patients.
Curr Oncol
; 22(6): e457-61, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26715883
16.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Ann Oncol
; 30(2): 161-165, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30624547
17.
Comparison of fluorodeoxyglucose uptake in symptomatic carotid artery and stable femoral artery plaques.
Br J Surg
; 101(4): 363-70, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24536009
18.
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Br J Cancer
; 108(4): 762-5, 2013 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23322195
19.
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ann Oncol
; 24(11): 2875-80, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24050956
20.
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
ESMO Open
; 8(6): 102065, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37988950